Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.9M 3.34M 3.11M 2.86M 373M 5.47M 36.94M 14.4M 187M 14.63M 14.32M 619M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.57M 3.91M 3.65M 3.35M 437M 6.41M 43.27M 16.87M 219M 17.14M 16.77M 725M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -0.38% | +3.41% | +2.61% | +23.81% | 51.22B | |
| -1.36% | +4.82% | +485.55% | +614.84% | 45.38B | |
| -2.04% | +3.69% | +19.34% | +91.23% | 41.97B | |
| +2.72% | +6.02% | +33.33% | +19.66% | 42.15B | |
| 0.00% | -3.91% | +18.49% | +47.98% | 31.95B | |
| -1.85% | +3.48% | - | - | 16.73B | |
| +0.72% | +5.27% | +31.55% | +145.37% | 17.1B | |
| -0.74% | +2.61% | +6.29% | +34.45% | 14.76B | |
| +0.50% | +3.62% | +82.64% | +46.53% | 13.91B | |
| Average | +0.87% | +3.24% | +84.98% | +127.98% | 30.58B | |
| Weighted average by Cap. | -0.27% | +3.18% | +103.54% | +150.73% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.4M -13.19M -12.3M -11.29M -1.47B -21.63M -146M -56.89M -738M -57.82M -56.57M -2.44B | 4.21M 3.06M 2.62M 2.44M 2.24M 292M 4.29M 28.97M 11.29M 147M 11.48M 11.23M 485M |
| Net Debt | 704K 511K 438K 408K 375K 48.91M 718K 4.84M 1.89M 24.51M 1.92M 1.88M 81.14M | 920K 668K 572K 534K 490K 63.91M 938K 6.33M 2.47M 32.03M 2.51M 2.45M 106M |
Employees
-
